{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T20:25:54Z","timestamp":1787862354493,"version":"build-2784847793"},"reference-count":39,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002744","name":"Bar-Ilan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002744","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.jbspin.2026.106110","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:07:55Z","timestamp":1784128075000},"page":"106110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The association between diabetes mellitus control and advanced anti-rheumatic treatment, among rheumatoid arthritis patients: A nation-wide based, retrospective, cohort study"],"prefix":"10.1016","volume":"93","author":[{"given":"Oriel","family":"Perets","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0395-4171","authenticated-orcid":false,"given":"Amir","family":"Bieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shay","family":"Brikman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Snait","family":"Ayalon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Assalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiola","family":"Atzeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadav","family":"Rappoport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad E.","family":"Naffaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2026.106110_bib0200","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1136\/ard.2010.145839","article-title":"Cardiovascular risk in rheumatoid arthritis and diabetes: How does it compare and when does it start?","volume":"70","author":"Nurmohamed","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2026.106110_bib0205","first-page":"1","article-title":"Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications","volume":"361","author":"England","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.jbspin.2026.106110_bib0210","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/rheumatology\/kex414","article-title":"High prevalence of diabetes in patients with rheumatoid arthritis: results from a questionnaire survey linked to claims data","volume":"57","author":"Albrecht","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2026.106110_bib0215","doi-asserted-by":"crossref","first-page":"e2552","DOI":"10.1097\/MD.0000000000002552","article-title":"Prevalence of undiagnosed diabetes in rheumatoid arthritis: an OGTT study","volume":"95","author":"Ursini","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jbspin.2026.106110_bib0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0146991","article-title":"Cardiovascular comorbidities relate more than others with disease activity in rheumatoid arthritis","volume":"11","author":"Crepaldi","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jbspin.2026.106110_bib0225","doi-asserted-by":"crossref","first-page":"e001724","DOI":"10.1136\/rmdopen-2021-001724","volume":"7","author":"Semb","year":"2021","journal-title":"RMD Open"},{"key":"10.1016\/j.jbspin.2026.106110_bib0230","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/nrrheum.2014.121","article-title":"Rheumatoid arthritis and metabolic syndrome","volume":"10","author":"Kerekes","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jbspin.2026.106110_bib0235","first-page":"1","article-title":"The impact of diabetes mellitus on treatment and outcomes of rheumatoid arthritis at 5-year follow-up: results from a multi-ethnic Asian cohort","volume":"5","author":"Xu","year":"2021","journal-title":"Rheumatol Adv Pract"},{"key":"10.1016\/j.jbspin.2026.106110_bib0240","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s40259-022-00561-7","article-title":"Rheumatoid arthritis treatment options and type 2 diabetes: unravelling the association","volume":"36","author":"Di Muzio","year":"2022","journal-title":"BioDrugs"},{"key":"10.1016\/j.jbspin.2026.106110_bib0245","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/XCE.0000000000000244","article-title":"The relationship between rheumatoid arthritis and diabetes mellitus: a systematic review and meta-analysis","volume":"10","author":"Tian","year":"2021","journal-title":"Cardiovasc Endocrinol Metab"},{"key":"10.1016\/j.jbspin.2026.106110_bib0250","doi-asserted-by":"crossref","first-page":"708168","DOI":"10.3389\/fmed.2021.708168","article-title":"Real-life retention rates and reasons for switching of biological DMARDs in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis","volume":"8","author":"Bhushan","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jbspin.2026.106110_bib0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.151988","article-title":"Factors influencing clinician prescribing of disease-modifying anti-rheumatic drugs for inflammatory arthritis: a systematic review and thematic synthesis of qualitative studies","volume":"55","author":"Lalor","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2026.106110_bib0260","doi-asserted-by":"crossref","first-page":"E1917065","DOI":"10.1001\/jamanetworkopen.2019.17065","article-title":"Which patients with rheumatoid arthritis will start biologics, how soon, and why\u00a0\u2013\u00a0much to learn from a universal coverage setting","volume":"2","author":"McCormick","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jbspin.2026.106110_bib0265","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1007\/s00296-018-4161-7","article-title":"Patterns of the initiation of disease-modifying antirheumatic drugs in incident rheumatoid arthritis: a German perspective based on nationwide ambulatory drug prescription data","volume":"38","author":"Steffen","year":"2018","journal-title":"Rheumatol Int"},{"issue":"1","key":"10.1016\/j.jbspin.2026.106110_bib0270","doi-asserted-by":"crossref","first-page":"105060","DOI":"10.1016\/j.jbspin.2020.07.009","article-title":"Time to initiation of biologic disease-modifying antirheumatic drugs in the French cohort ESPOIR","volume":"88","author":"Kedra","year":"2021","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2026.106110_bib0275","doi-asserted-by":"crossref","first-page":"E1917053","DOI":"10.1001\/jamanetworkopen.2019.17053","article-title":"Association of patient, prescriber, and region with the initiation of first prescription of biologic disease-modifying antirheumatic drug among older patients with rheumatoid arthritis and identical health insurance coverage","volume":"2","author":"Tatangelo","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jbspin.2026.106110_bib0280","doi-asserted-by":"crossref","first-page":"3866","DOI":"10.1093\/rheumatology\/kead143","article-title":"Characteristics of patients with difficult-to-treat rheumatoid arthritis in a French single-centre hospital","volume":"62","author":"Hecquet","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2026.106110_bib0285","doi-asserted-by":"crossref","first-page":"e1928","DOI":"10.1002\/msc.1928","article-title":"Drug survival on first biologic therapy among late-onset rheumatoid arthritis patients compared to early-onset patients: a population-based cohort study","volume":"22","author":"Jeries","year":"2024","journal-title":"Musculoskeletal Care"},{"key":"10.1016\/j.jbspin.2026.106110_bib0290","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.critrevonc.2016.11.003","article-title":"Hyperglycemia, tumorigenesis, and chronic inflammation","volume":"108","author":"Chang","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jbspin.2026.106110_bib0295","doi-asserted-by":"crossref","first-page":"e0290791","DOI":"10.1371\/journal.pone.0290791","article-title":"Type 2 diabetes remission trajectories and variation in risk of diabetes complications: a population-based cohort study","volume":"18","author":"Dambha-Miller","year":"2023","journal-title":"PLoS One"},{"issue":"Suppl. 1","key":"10.1016\/j.jbspin.2026.106110_bib0300","first-page":"S183","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2026","volume":"49","year":"2026","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jbspin.2026.106110_bib0305","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13012-014-0153-5","article-title":"Factors influencing rheumatologists\u2019 prescription of biological treatment in rheumatoid arthritis: an interview study","volume":"9","author":"Kalkan","year":"2014","journal-title":"Implement Sci"},{"key":"10.1016\/j.jbspin.2026.106110_bib0310","doi-asserted-by":"crossref","first-page":"15051","DOI":"10.1038\/s41598-021-94504-x","article-title":"Changes in the use patterns of bDMARDs in patients with rheumatic diseases over the past 13\u00a0years","volume":"11","author":"S\u00e1nchez-Piedra","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jbspin.2026.106110_bib0315","doi-asserted-by":"crossref","first-page":"105057","DOI":"10.1016\/j.jbspin.2020.07.006","article-title":"Risk factors associated with initiation of a biologic disease modifying anti-rheumatic drug in patients with rheumatoid arthritis: a nested case-control study on 34,925 patients","volume":"88","author":"Park","year":"2021","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2026.106110_bib0320","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1001\/jama.2009.1347","article-title":"Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: the LANCET randomized trial","volume":"302","author":"Pradhan","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jbspin.2026.106110_bib0325","first-page":"800","article-title":"Inflammatory markers and control of type 2 diabetes mellitus. Diabetes and metabolic syndrome","volume":"13","author":"Elimam","year":"2019","journal-title":"Clin Res Rev"},{"key":"10.1016\/j.jbspin.2026.106110_bib0330","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12902-020-00584-7","article-title":"The association of erythrocyte sedimentation rate, high-sensitivity C-reactive protein and diabetic kidney disease in patients with type 2 diabetes","volume":"20","author":"Guo","year":"2020","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.jbspin.2026.106110_bib0335","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s40259-021-00498-3","article-title":"Large-scale postmarketing surveillance of biological drugs for immune-mediated inflammatory diseases through an italian distributed multi-database healthcare network: the VALORE project","volume":"35","author":"Trifir\u00f2","year":"2021","journal-title":"Biodrugs"},{"key":"10.1016\/j.jbspin.2026.106110_bib0340","doi-asserted-by":"crossref","first-page":"5567","DOI":"10.1093\/rheumatology\/keab148","article-title":"Type 2 diabetes mellitus, glycaemic control, associated therapies and risk of rheumatoid arthritis: a retrospective cohort study","volume":"60","author":"Zemedikun","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2026.106110_bib0345","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/art.41190","article-title":"Insulin-resistant pathways are associated with disease activity in rheumatoid arthritis and are subject to disease modification through metabolic reprogramming: a potential novel therapeutic approach","volume":"72","author":"Gallagher","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2026.106110_bib0350","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/03009742.2019.1695928","article-title":"Adherence to metformin and the onset of rheumatoid arthritis: a population-based cohort study","volume":"49","author":"Naffaa","year":"2020","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.jbspin.2026.106110_bib0355","doi-asserted-by":"crossref","first-page":"763","DOI":"10.55563\/clinexprheumatol\/zn2u9h","article-title":"Metformin repositioning in rheumatoid arthritis","volume":"39","author":"Matsuoka","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jbspin.2026.106110_bib0360","doi-asserted-by":"crossref","first-page":"3094642","DOI":"10.1155\/2016\/3094642","article-title":"Anti-inflammatory effects of GLP-1-based therapies beyond glucose control","volume":"2016","author":"Lee","year":"2016","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.jbspin.2026.106110_bib0365","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41584-025-01302-0","article-title":"Glucagon-like peptide-1 receptor agonists in arthritis: current insights and future directions","volume":"21","author":"Karacabeyli","year":"2025","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jbspin.2026.106110_bib0370","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X261425441","article-title":"The association between glucagon-like peptide-1 receptor agonist and rheumatoid arthritis: a population-based case-control study","volume":"18","author":"Israel","year":"2026","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.jbspin.2026.106110_bib0375","article-title":"SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease","volume":"11","author":"Kim","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jbspin.2026.106110_bib0380","doi-asserted-by":"crossref","first-page":"e085196","DOI":"10.1136\/bmj-2025-085196","article-title":"Sodium-glucose cotransporter-2 inhibitors and risk of autoimmune rheumatic diseases: population based cohort study","volume":"391","author":"Hong","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.jbspin.2026.106110_bib0385","doi-asserted-by":"crossref","first-page":"103493","DOI":"10.1016\/j.jaut.2025.103493","article-title":"Comparative risk of rheumatoid arthritis between glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in type 2 diabetes","volume":"157","author":"Yen","year":"2025","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jbspin.2026.106110_bib0390","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1136\/ard-2023-224242","article-title":"SGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagy","volume":"82","author":"Zhao","year":"2023","journal-title":"Ann Rheum Dis"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X26000795?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X26000795?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T20:10:13Z","timestamp":1787861413000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X26000795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S1297319X26000795"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2026.106110","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The association between diabetes mellitus control and advanced anti-rheumatic treatment, among rheumatoid arthritis patients: A nation-wide based, retrospective, cohort study","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2026.106110","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 Fran\u00e7aise de Rhumatologie.","name":"copyright","label":"Copyright"}],"article-number":"106110"}}